JP2023517043A5 - - Google Patents
Info
- Publication number
- JP2023517043A5 JP2023517043A5 JP2022553213A JP2022553213A JP2023517043A5 JP 2023517043 A5 JP2023517043 A5 JP 2023517043A5 JP 2022553213 A JP2022553213 A JP 2022553213A JP 2022553213 A JP2022553213 A JP 2022553213A JP 2023517043 A5 JP2023517043 A5 JP 2023517043A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- salt according
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062985937P | 2020-03-06 | 2020-03-06 | |
| US62/985,937 | 2020-03-06 | ||
| US202063040051P | 2020-06-17 | 2020-06-17 | |
| US63/040,051 | 2020-06-17 | ||
| PCT/IB2021/051764 WO2021176366A1 (en) | 2020-03-06 | 2021-03-03 | Inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023517043A JP2023517043A (ja) | 2023-04-21 |
| JP2023517043A5 true JP2023517043A5 (enExample) | 2024-03-13 |
Family
ID=74859494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022553213A Pending JP2023517043A (ja) | 2020-03-06 | 2021-03-03 | ヒト免疫不全ウイルスの複製阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230355626A1 (enExample) |
| EP (1) | EP4114834A1 (enExample) |
| JP (1) | JP2023517043A (enExample) |
| KR (1) | KR20220151655A (enExample) |
| CN (1) | CN115551858A (enExample) |
| AU (2) | AU2021231447A1 (enExample) |
| BR (1) | BR112022017832A2 (enExample) |
| CA (1) | CA3170536A1 (enExample) |
| CL (1) | CL2022002405A1 (enExample) |
| IL (1) | IL296182A (enExample) |
| MX (1) | MX2022011016A (enExample) |
| WO (1) | WO2021176366A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121335877A (zh) | 2023-06-15 | 2026-01-13 | Viiv保健英国第五有限公司 | 用于制备化合物的方法和中间体 |
| TW202547514A (zh) * | 2024-02-05 | 2025-12-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| AU2014340110B2 (en) | 2013-10-24 | 2018-07-12 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| US9855230B2 (en) | 2014-09-09 | 2018-01-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2016172425A1 (en) | 2015-04-23 | 2016-10-27 | Viiv Healthcare (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US10221129B2 (en) | 2015-04-23 | 2019-03-05 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| CN119462611A (zh) | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 |
| EP3752496B1 (en) | 2018-02-16 | 2023-07-05 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| EP3774775B8 (en) * | 2018-04-11 | 2023-11-15 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| JP7433303B2 (ja) * | 2018-09-20 | 2024-02-19 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| EP3873607B1 (en) * | 2018-10-29 | 2023-11-29 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
| JP2022506399A (ja) * | 2018-11-05 | 2022-01-17 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| US20210395248A1 (en) * | 2018-11-05 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| UY38559A (es) * | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| BR112021025655A2 (pt) * | 2019-06-19 | 2022-02-01 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| JP7703538B2 (ja) * | 2019-12-09 | 2025-07-07 | ヴィーブ、ヘルスケア、カンパニー | カボテグラビルを含んでなる医薬組成物 |
-
2021
- 2021-03-03 KR KR1020227034569A patent/KR20220151655A/ko active Pending
- 2021-03-03 AU AU2021231447A patent/AU2021231447A1/en not_active Abandoned
- 2021-03-03 JP JP2022553213A patent/JP2023517043A/ja active Pending
- 2021-03-03 US US17/802,194 patent/US20230355626A1/en active Pending
- 2021-03-03 MX MX2022011016A patent/MX2022011016A/es unknown
- 2021-03-03 BR BR112022017832A patent/BR112022017832A2/pt unknown
- 2021-03-03 EP EP21710351.4A patent/EP4114834A1/en not_active Withdrawn
- 2021-03-03 CN CN202180032445.6A patent/CN115551858A/zh active Pending
- 2021-03-03 CA CA3170536A patent/CA3170536A1/en active Pending
- 2021-03-03 IL IL296182A patent/IL296182A/en unknown
- 2021-03-03 WO PCT/IB2021/051764 patent/WO2021176366A1/en not_active Ceased
-
2022
- 2022-09-05 CL CL2022002405A patent/CL2022002405A1/es unknown
-
2024
- 2024-03-15 AU AU2024201719A patent/AU2024201719A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023517043A5 (enExample) | ||
| AU2020348685B2 (en) | IL-17A modulators and uses thereof | |
| US20260028329A1 (en) | Jak1 selective inhibitors | |
| JP7580136B2 (ja) | Ｊａｋ阻害剤化合物及びその使用 | |
| CN102164912B (zh) | 制备喹诺酮类化合物的工艺 | |
| JP7222590B2 (ja) | ３－アザビシクロ［３，１，１］ヘプタン誘導体及びこれを含む薬学的組成物 | |
| JP2023509495A (ja) | ＲＯＲγｔ阻害剤、その製造方法及び使用 | |
| JP2012509309A (ja) | Ｆａａｈ阻害剤としての１−オキサ−８−アザスピロ［４．５］デカン−８−カルボキサミド化合物 | |
| CN105228620A (zh) | 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物 | |
| WO2025053850A1 (en) | Covalent kras-binding compounds for medical treatment | |
| JP2009526037A (ja) | トリアゾロピリジン化合物 | |
| JP2014530207A (ja) | 縮合環を有するオキサゾリドン（ｏｘａｚｏｌｉｄｏｎｅ）類の抗菌物質 | |
| WO2023283453A1 (en) | Phenyl acetamide based il-17a modulators and uses thereof | |
| JP2022551256A5 (enExample) | ||
| KR20190129034A (ko) | 금속효소 억제제 화합물 | |
| JP2022551254A5 (enExample) | ||
| CA3015166C (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| JP2023517312A5 (enExample) | ||
| WO2021064677A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| IL296182A (en) | Inhibitors of human immunodeficiency virus replication | |
| WO2022217118A1 (en) | Pyrimidine based ras modulators and uses thereof | |
| JP7168245B2 (ja) | 三環式化合物 | |
| JP2022541772A (ja) | インターロイキンの調節におけるプロドラッグ | |
| CA3253274A1 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE LPA RECIPIENT | |
| WO2019042442A1 (zh) | 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物 |